Cystic fibrosis
Education on Cystic fibrosis and Alpha-1 Antitrypsin research from the Mark Egly Foundation, with patent claims clearly labeled as hypothesis.
Research hypothesis, not medical advice
The connections described on this page come from Mark Egly's patent filing and ongoing research. They are not established medical facts. Always work with your physician for diagnosis and treatment.
Research hypothesis. The connection between Cystic fibrosis and Alpha-1 Antitrypsin is described in Mark Egly's 2020 patent filing. This is not established medical fact and is not medical advice. Always talk with your doctor about your own health.
What is Cystic fibrosis?
Cystic fibrosis is a health condition discussed in Mark Egly's research on Alpha-1 Antitrypsin. Respiratory conditions affect the lungs and breathing. AAT is well known for protecting lung tissue from enzyme damage.
What Mark Egly's patent discusses
Due to the link between AATD and cystic fibrosis, in one embodiment AAT may be used to treat and control cystic fibrosis in patients, including the side effects of cystic fibrosis, either with or without known AATD. A diagnosis of cystic fibrosis may prompt a medical provider to test a patient for AATD. Alternatively, a patient diagnosed with cystic fibrosis may seek genetic testing for AATD through an independent genetic testing company such as 23andMe or geneology.com, a pharmaceutical company supplied test kit or other private methods available. A method for treating a patient suffering from cystic fibrosis with AAT begins with the step of determining if the patient is AAT deficient or has lower AAT levels without being AATD. Determining if the patient is AAT deficient or has lower AAT levels without being AATD proceeds as previously described in this disclosure in the section entitled "Determining if a patient is AAT deficient or in the state of having low circulating AAT without being AAT deficient." If the genotyping assay obtained from determining if the patient is AAT deficient indicates that the patient has a SERPINA1 AAT deficient genotype or if the patient's circulating…
How this may relate to Alpha-1
Mark Egly's patent proposes that when the body has too little working Alpha-1 Antitrypsin, or when neutrophils release too much neutrophil elastase, inflammation and tissue damage may worsen. For Cystic fibrosis, the patent suggests that testing for AATD or low circulating AAT could help guide care. This is a research hypothesis, not a proven treatment path for everyone with this condition.
What you can do
If you or a family member lives with Cystic fibrosis, consider learning about Alpha-1 Antitrypsin Deficiency and discussing AAT testing with your healthcare team. The Mark Egly Foundation offers education and community support: